1. Home
  2. SAMG vs GANX Comparison

SAMG vs GANX Comparison

Compare SAMG & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silvercrest Asset Management Group Inc.

SAMG

Silvercrest Asset Management Group Inc.

HOLD

Current Price

$13.43

Market Cap

125.5M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.93

Market Cap

112.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAMG
GANX
Founded
2002
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
125.5M
112.7M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
SAMG
GANX
Price
$13.43
$1.93
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.20
AVG Volume (30 Days)
19.0K
801.9K
Earning Date
03-16-2026
04-06-2026
Dividend Yield
6.31%
N/A
EPS Growth
N/A
47.95
EPS
0.56
N/A
Revenue
$91,358,000.00
$55,180.00
Revenue This Year
$12.83
N/A
Revenue Next Year
$3.62
N/A
P/E Ratio
$23.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.00
$1.41
52 Week High
$16.97
$4.34

Technical Indicators

Market Signals
Indicator
SAMG
GANX
Relative Strength Index (RSI) 30.08 38.59
Support Level N/A $1.60
Resistance Level $16.66 $1.99
Average True Range (ATR) 0.57 0.24
MACD -0.20 -0.11
Stochastic Oscillator 13.89 4.93

Price Performance

Historical Comparison
SAMG
GANX

About SAMG Silvercrest Asset Management Group Inc.

Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: